International Health
Volume 1, Issue 2 , Pages 190-195 , December 2009

Caffeine for the management of apnea in preterm infants

  • Eunice Mueni

      Affiliations

    • KEMRI/Wellcome Trust Research Programme, Nairobi, Kenya
    • Corresponding Author InformationCorresponding author at: P.O. Box 43640, 00100 GPO, Nairobi, Kenya Tel.: +254 20 2715160; fax: +254 20 2717673.
    • ,
  • Newton Opiyo

      Affiliations

    • KEMRI/Wellcome Trust Research Programme, Nairobi, Kenya
    • ,
  • Mike English

      Affiliations

    • KEMRI/Wellcome Trust Research Programme, Nairobi, Kenya
    • Department of Paediatrics, University of Oxford, Oxford, UK

Received 4 June 2009 ,Revised 19 August 2009 ,Accepted 13 September 2009.

References 

  1. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354:2112–2121
  2. WHO. WHO Pocket Book of Hospital Care for Children: guidelines for the management of common illnesses with limited resources. Available at www.ichrc.org (accessed 10 February 2009).
  3. Mehta VB, Robert ES. Treatment of apnea of prematurity. Pediatric Drugs. 2000;5:195–210
  4. Hochwald C, Kennedy K, Chang J, Moya F. A randomized, controlled, double- blind trial comparing two loading doses of aminophylline. J Perinatol. 2002;22:275–278
  5. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo- controlled study. Pharmacotherapy. 2000;20:644–652
  6. Steer PA, Henderson-Smart DJ. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2000;2:CD000273
  7. Henderson-Smart DJ, Steer PA. Prophylactic methylxanthine for preventing of apnea in preterm infants. Cochrane Database Syst Rev. 2000;2:CD000432
  8. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357:1893–1902
  9. Henderson-Smart DJ, Steer PA. Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants. Cochrane Database Syst Rev. 2001;4:CD000048
  10. Murat I, Moriette G, Blin MC, Couchard M, Flouvat B, De Gamarra E, et al. The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. J Pediatr. 1981;99:984–989
  11. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev. 2001;3:CD000140
  12. Scanlon JE, Chin KC, Morgan ME, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea?. Arch Dis Child. 1992;67:425–428
  13. Bairam , Boutroy MJ, Badonnel Y, Vert P. Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. J Pediatr. 1987;110:636–639
  14. Brouard C, Morriette G, Murat I, Fluovat B, Pajot N, Walti H, et al. Comparative Efficacy of Theophylline and Caffeine in the Treatment of Idiopathic Apnea in Premature Infants. Am J Dis Child. 1985;139:698–700
  15. Bucher HU, Duc G. Does caffeine prevent hypoxaemic episodes in premature infants? A randomized controlled trial. Eur J Pediatr. 1988;147:288–291
  16. Levitt GA, Harvey DR. The use of prophylactic caffeine in the prevention of neonatal apnoeic attacks. Unpublished manuscript. Levitt GA, Mushin A, Bellman S, Harvey DR. Outcome of preterm infants who suffered neonatal apnoeic attacks. Early Hum Dev 1988; 16:235-243.
  17. LeBard SE, Kurth CD, Spitzer AR, Downes JJ. Preventing postoperative apnea by neuromodulator antagonists. Anesthesiology. 1989;71:A1026
  18. Welborn LG, De Soto H, Hannallah RS, Fink R, Ruttimann UE, Boeckx R. The use of caffeine in the control of post-anesthetic apnea in former premature infants. Anesthesiology. 1988;68:796–798
  19. Welborn LG, Hannallah RS, Fink R, Ruttimann UE, Hicks JM. High-dose caffeine suppresses postoperative apnea in former preterm infants. Anesthesiology. 1989;71:347–349
  20. Davis P, Schmidt B, Robert R, Doyle L, Asztalos E, Haslam R, Sinha S, Tin W, The CAP investigators. Caffeine for apnea of prematurity (CAP) trial: benefits may vary in subgroups. Abstract of the paper presented in Hawaii in May 2008.
  21. Neonatal Formulary 5: Caffeine Citrate (Comment). www.blackwellpublishing.com/medicine/bmj/nnf5/pdfs/comment/caffeine1.pdf (accessed 22 April 2009).
  22. British National Formulary (BNF) for children, 2008. www.bnfc.org/bnfc/ (accessed 26 February 2009).
  23. KEMSA. Kenya Medical Supplies Agencies (KEMSA). Available at: http://www.kemsa.co.ke/datagrids/kemsa_commodity_catalogue.php.
  24. Joy L, Kate K. Opportunities for Africa's newborns. Practical data, policy and pragmmatic support for newborn care for Africa. The Partnerships for Maternal. Newborn and Child Health. 2006;2006;www.who.int/pmnch/media/publications/africanewborns/en/index.html (accessed 7 August 2009)
  25. Lawn JE, Cousens S, Zupan J. Lancet Neonatal Survival Steering Team. 4 Million neonatal deaths: when? Where? Why?. Lancet. 2005;365:891–900

PII: S1876-3413(09)00042-4

doi: 10.1016/j.inhe.2009.09.005

International Health
Volume 1, Issue 2 , Pages 190-195 , December 2009

Article Tools